drugset / Trial / NCT01123304
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-03
- Completion
- 2012-03
Outcome
Outcome not reported
Stopped: “This study has been terminated due to lack of availability of investigational product.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MORAb-028 | Monoclonal antibody | 1 mg/ml | Other |
| Subject | MORAb-028 | Monoclonal antibody | 2 mg/ml | Other |